|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–e386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ministry of Health and Welfare, . 2021
Cancer Registry Annual Report. https://twcr.tw/wp-content/uploads/2024/02/Top-10-cancers-in-Taiwan-2021.pdfDecember
18–2024
|
|
4
|
Health Promotion Administration and
Ministry of Health Welfare, . 2023 Health Promotion Administration
Annual Report. https://www.hpa.gov.tw/EngPages/Detail.aspx?nodeid=1070&pid=18165December
18–2024
|
|
5
|
Warnakulasuriya S: Global epidemiology of
oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pedruzzi PAG, Kowalski LP, Nishimoto IN,
Oliveira BV, Tironi F and Ramos GHA: Analysis of prognostic factors
in patients with oropharyngeal squamous cell carcinoma treated with
radiotherapy alone or in combination with systemic chemotherapy.
Arch Otolaryngol Head Neck Surg. 134:1196–1204. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ishida K, Tomita H, Nakashima T, Hirata A,
Tanaka T, Shibata T and Hara A: Current mouse models of oral
squamous cell carcinoma: Genetic and chemically induced models.
Oral Oncol. 73:16–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin CS, Lin YC, Adebayo BO, Wu A, Chen JH,
Peng YJ, Cheng MF, Lee WH, Hsiao M, Chao TY and Yeh CT: Silencing
JARID1B suppresses oncogenicity, stemness and increases radiation
sensitivity in human oral carcinoma. Cancer Lett. 368:36–45. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koch FP, Kunkel M, Biesterfeld S and
Wagner W: Diagnostic efficiency of differentiating small cancerous
and precancerous lesions using mucosal brush smears of the oral
cavity-a prospective and blinded study. Clin Oral Investig.
15:763–769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hadzic S, Gojkov-Vukelic M, Pasic E and
Dervisevic A: Importance of early detection of potentially
malignant lesions in the prevention of oral cancer. Mater Sociomed.
29:129–133. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
D'Souza W and Saranath D: Clinical
implications of epigenetic regulation in oral cancer. Oral Oncol.
51:1061–1068. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hema KN, Smitha T, Sheethal HS and
Mirnalini SA: Epigenetics in oral squamous cell carcinoma. J Oral
Maxillofac Pathol. 21:252–259. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li YF, Hsiao YH, Lai YH, Chen YC, Chen YJ,
Chou JL, Chan MW, Lin YH, Tsou YA, Tsai MH and Tai CK: DNA
methylation profiles and biomarkers of oral squamous cell
carcinoma. Epigenetics. 10:229–236. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lizen B, Moens C, Mouheiche J, Sacré T,
Ahn MT, Jeannotte L, Salti A and Gofflot F: Conditional loss of
Hoxa5 function early after birth impacts on expression of genes
with synaptic function. Front Mol Neurosci. 10:3692017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Landry-Truchon K, Houde N, Boucherat O,
Joncas FH, Dasen JS, Philippidou P, Mansfield JH and Jeannotte L:
HOXA5 plays tissue-specific roles in the developing respiratory
system. Development. 144:3547–3561. 2017.PubMed/NCBI
|
|
16
|
Raman V, Martensen SA, Reisman D, Evron E,
Odenwald WF, Jaffee E, Marks J and Sukumar S: Compromised HOXA5
function can limit p53 expression in human breast tumours. Nature.
405:974–978. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kikuyama M, Takeshima H, Kinoshita T,
Okochi-Takada E, Wakabayashi M, Akashi-Tanaka S, Ogawa T, Seto Y
and Ushijima T: Development of a novel approach, the
epigenome-based outlier approach, to identify tumor-suppressor
genes silenced by aberrant DNA methylation. Cancer Lett.
322:204–212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Conway K, Edmiston SN, May R, Kuan PF, Chu
H, Bryant C, Tse CK, Swift-Scanlan T, Geradts J, Troester MA and
Millikan RC: DNA methylation profiling in the Carolina breast
cancer study defines cancer subclasses differing in
clinicopathologic characteristics and survival. Breast Cancer Res.
16:4502014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Daugaard I, Dominguez D, Kjeldsen TE,
Kristensen LS, Hager H, Wojdacz TK and Hansen LL: Identification
and validation of candidate epigenetic biomarkers in lung
adenocarcinoma. Sci Rep. 6:358072016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Martinez R, Carmona FJ, Vizoso M, Rohde V,
Kirsch M, Schackert G, Ropero S, Paulus W, Barrantes A, Gomez A and
Esteller M: DNA methylation alterations in grade II- and anaplastic
pleomorphic xanthoastrocytoma. BMC Cancer. 14:2132014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kanai M, Hamada J, Takada M, Asano T,
Murakawa K, Takahashi Y, Murai T, Tada M, Miyamoto M, Kondo S and
Moriuchi T: Aberrant expressions of HOX genes in colorectal and
hepatocellular carcinomas. Oncol Rep. 23:843–851. 2010.PubMed/NCBI
|
|
22
|
Rodini CO, Xavier FCA, Paiva KBS, De Souza
Setúbal Destro MF, Moyses RA, Michaluarte P, Carvalho MB, Fukuyama
EE; Head and Neck Genome Project Gencapo, ; Tajara EH, et al:
Homeobox gene expression profile indicates HOXA5 as a candidate
prognostic marker in oral squamous cell carcinoma. Int J Oncol.
40:1180–1188. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wong DY, Chang KW, Chen CF and Chang RC:
Characterization of two new cell lines derived from oral cavity
human squamous cell carcinomas-OC1 and OC2. J Oral Maxillofac Surg.
48:385–390. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lai YH, He RY, Chou JL, Chan MWY, Li YF
and Tai CK: Promoter hypermethylation and silencing of tissue
factor pathway inhibitor-2 in oral squamous cell carcinoma. J
Transl Med. 12:2372014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gillan L, Matei D, Fishman DA, Gerbin CS,
Karlan BY and Chang DD: Periostin secreted by epithelial ovarian
carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5)
integrins and promotes cell motility. Cancer Res. 62:5358–5364.
2002.PubMed/NCBI
|
|
27
|
Shichinohe T, Bochner BH, Mizutani K,
Nishida M, Hegerich-Gilliam S, Naldini L and Kasahara N:
Development of lentiviral vectors for antiangiogenic gene delivery.
Cancer Gene Ther. 8:879–889. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen YJ, Chen SY, Lovel R, Ku YC, Lai YH,
Hung CL, Li YF, Lu YC and Tai CK: Enhancing chemosensitivity in
oral squamous cell carcinoma by lentivirus vector-mediated RNA
interference targeting EGFR and MRP2. Oncol Lett. 12:2107–2114.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kirch HC, Flaswinkel S, Rumpf H, Brockmann
D and Esche H: Expression of human p53 requires synergistic
activation of transcription from the p53 promoter by AP-1,
NF-kappaB and Myc/Max. Oncogene. 18:2728–2738. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kaiser AM and Attardi LD: Deconstructing
networks of p53-mediated tumor suppression in vivo. Cell Death
Differ. 25:93–103. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mello SS and Attardi LD: Deciphering p53
signaling in tumor suppression. Curr Opin Cell Biol. 51:65–72.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Andreadis C, Vahtsevanos K, Sidiras T,
Thomaidis I, Antoniadis K and Mouratidou D: 5-Fluorouracil and
cisplatin in the treatment of advanced oral cancer. Oral Oncol.
39:380–385. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jo DW, Kim YK and Yun PY: The influence of
p53 mutation status on the anti-cancer effect of cisplatin in oral
squamous cell carcinoma cell lines. J Korean Assoc Oral Maxillofac
Surg. 42:337–344. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Watson RE, Curtin GM, Hellmann GM,
Doolittle DJ and Goodman JI: Increased DNA methylation in the HoxA5
promoter region correlates with decreased expression of the gene
during tumor promotion. Mol Carcinog. 41:54–66. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Novak P, Jensen T, Oshiro MM, Wozniak RJ,
Nouzova M, Watts GS, Klimecki WT, Kim C and Futscher BW: Epigenetic
inactivation of the HOXA gene cluster in breast cancer. Cancer Res.
66:10664–10670. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang SH, Liao PH, Pan YF, Chen SL, Chou SS
and Chou MY: The novel p53-dependent metastatic and apoptotic
pathway induced by vitexin in human oral cancer OC2 cells.
Phytother Res. 27:1154–1161. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yeh YT, Yeh H, Su SH, Lin JS, Lee KJ, Shyu
HW, Chen ZF, Huang SY and Su SJ: Phenethyl isothiocyanate induces
DNA damage-associated G2/M arrest and subsequent apoptosis in oral
cancer cells with varying p53 mutations. Free Radic Biol Med.
74:1–13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ho CC, Yang XW, Lee TL, Liao PH, Yang SH,
Tsai CH and Chou MY: Activation of p53 signalling in
acetylsalicylic acid-induced apoptosis in OC2 human oral cancer
cells. Eur J Clin Invest. 33:875–882. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Olivier M, Hollstein M and Hainaut P: TP53
mutations in human cancers: Origins, consequences, and clinical
use. Cold Spring Harb Perspect Biol. 2:a0010082010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lindemann A, Takahashi H, Patel AA, Osman
AA and Myers JN: Targeting the DNA damage response in OSCC with
TP53 mutations. J Dent Res. 97:635–644. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen H, Chung S and Sukumar S:
HOXA5-induced apoptosis in breast cancer cells is mediated by
caspases 2 and 8. Mol Cell Biol. 24:924–935. 2004. View Article : Google Scholar : PubMed/NCBI
|
